ArticleNature microbiology2016
A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse.
Article in Nature microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 105 citations in OpenAlex.
- A case-control study of blood group antigen expression in Babesia microti infected patients in the United States.Transfusion · 2026Article
- Tafenoquine: A Breakthrough Option for Babesiosis Treatment.Tropical medicine and infectious disease · 2026Article
- Article
- Natural products against Babesiosis: active compounds, molecular mechanisms, application limitations and translational development.Frontiers in cellular and infection microbiology · 2026Review
- Article
- An Alarming Public Health Problem: Ticks and Tick-Borne Pathogens in Urban Recreational Parks.China CDC weekly · 2025Article
- Design and screening of novel molecular compounds targeting lactate dehydrogenase of Babesia microti.Parasites & vectors · 2025Article
- Persistent human babesiosis with low-grade parasitemia, challenges for clinical diagnosis and management.Heliyon · 2024Review
- Evaluating Antimalarial Proteasome Inhibitors for Efficacy inACS omega · 2024Article
- Article
- DoTropical medicine and infectious disease · 2024Article
- Tafenoquine for Relapsing Babesiosis: A Case Series.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Transfusion-transmittedJournal of clinical microbiology · 2023Review
- Article
- Relapsing Babesiosis With Molecular Evidence of Resistance to Certain Antimicrobials Commonly Used to TreatOpen forum infectious diseases · 2023Review
- Article
- Advances inPathogens (Basel, Switzerland) · 2023Review
- Anti-parasitic drug discovery againstFrontiers in cellular and infection microbiology · 2023Article
- The impact of ABO and RhD blood types on Babesia microti infection.PLoS neglected tropical diseases · 2023Article
- Comparative single-cell transcriptional atlases of Babesia species reveal conserved and species-specific expression profiles.PLoS biology · 2022Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 1 country.
Funding
Abstract
Human babesiosis caused by Babesia microti is an emerging tick-borne zoonosis of increasing importance due to its rising incidence and expanding geographic range(1). Infection with this organism, an intraerythrocytic parasite of the phylum Apicomplexa, causes a febrile syndrome similar to malaria(2). Relapsing disease is common among immunocompromised and asplenic individuals(3,4) and drug resistance has recently been reported(5). To investigate the origin and genetic diversity of this parasite, we sequenced the complete genomes of 42 B. microti samples from around the world, including deep coverage of clinical infections at endemic sites in the continental USA. Samples from the continental USA segregate into a Northeast lineage and a Midwest lineage, with subsequent divergence of subpopulations along geographic lines. We identify parasite variants that associate with relapsing disease, including amino acid substitutions in the atovaquone-binding regions of cytochrome b (cytb) and the azithromycin-binding region of ribosomal protein subunit L4 (rpl4). Our results shed light on the origin, diversity and evolution of B. microti, suggest possible mechanisms for clinical relapse, and create the foundation for further research on this emerging pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.